Skip to main content
. 2016 Oct 6;10:679. doi: 10.3332/ecancer.2016.679

Table 5. Comparison studies of Sokal, Euro and EUTOS scores in imatinib era.

Reference Predictive Implication Prognostic Implication
Marin et al (UK) [34] EUTOS not predictive of CCyR, MMR. Sokal has predictive efficacy. EUTOS not prognostic of PFS, OS. Sokal has prognostic efficacy.
Yamamoto et al
(Japan) [2]
EUTOS not predictive of CCyR or MMR. Sokal and Euro have predictive efficacy. EUTOS not prognostic of EFS, PFS, OS. Sokal and Euro have prognostic efficacy.
Hasford et al
(Europe) [7]
EUTOS better predictive of CCyR. Sokal or Euro do not have predictive efficacy. EUTOS better prognostic of PFS. Sokal or Euro do not have prognostic efficacy.
Tao et al (China) [33] EUTOS better predictor of CCyR. Sokal and Euro unable to differentiate intermediate Vs high risk for CCyR. EUTOS better prognostic of PFS and OS. Sokal unable to differentiate low Vs intermediate risk for OS. Euro unable to differentiate intermediate Vs high risk for PFS and OS.
Present study (India) EUTOS, Sokal, and Euro scores predictive of cumulative incidence of CCyR and MMR EUTOS better predictor of PFS and OS. Sokal and Euro unable to differentiate low and intermediate risk for PFS and OS.